Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.63 USD | +0.87% | +9.07% | -81.37% |
05-14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
05-10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-81.37% | 162M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-1.11% | 21.97B | |
-5.20% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4